Top in endocrinology: Tirzepatide for obesity treatment; successes in time-restricted eating
Click Here to Manage Email Alerts
The FDA has recently approved injectable tirzepatide for chronic weight management in adults with overweight or obesity and at least one weight-related condition, such as high BP, type 2 diabetes or higher cholesterol.
Katherine H. Saunders, MD, DABOM, co-founder of Intellihealth and clinical assistant professor of medicine at Weill Cornell Medicine, told Healio that the approval “is a tremendous milestone in the history of obesity medicine.” It was the top story in endocrinology last week.
The second top story was about a study that showed time-restricted eating was associated with greater weight loss in adults with type 2 diabetes and obesity than calorie restriction or continuing eating habits.
Read these and more top stories in endocrinology below:
Tirzepatide earns FDA approval for obesity treatment
The FDA approved the injectable GIP/GLP-1 dual incretin-based agonist tirzepatide for chronic weight management among adults with obesity, according to a press release. Read more.
Time-restricted eating reduces weight, HbA1c for adults with type 2 diabetes
Adults with type 2 diabetes and obesity achieved greater weight loss with time-restricted eating at 6 months than with calorie restriction or continuing usual eating habits, according to study data. Read more.
Lifestyle medicine foundation for treating people with obesity
Lifestyle medicine is a central component of obesity treatment, including for adults who receive anti-obesity medications or undergo bariatric surgery, according to three speakers at the Lifestyle Medicine Conference. Read more.
FDA warns people with diabetes to avoid product sold for blood glucose management
The FDA issued a warning for consumers to avoid using a nonprescription product currently being sold for blood glucose management due to risks for adverse events, according to an agency press release. Read more.
Q&A: How to address eating disorders in type 1 diabetes
Susan Weiner, MS, RDN, CDCES, FADCES, talks with Erin Phillips, MPH, RD, CDCES, about how diabetes care and education specialists can address the risk for eating disorders after a diagnosis of type 1 diabetes. Read more.